Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet

BACKGROUND: Saroglitazar is a novel PPAR-α/γ agonist with predominant PPAR-α activity. In various preclinical models, saroglitazar has been shown to prevent & reverse symptoms of NASH. In view of these observations, and the fact that NASH is a progressive disease leading to HCC, we hypothesized...

Descripción completa

Detalles Bibliográficos
Autores principales: Giri, Suresh R., Bhoi, Bibhuti, Trivedi, Chitrang, Rath, Akshyaya, Rathod, Rohan, Sharma, Anish, Ranvir, Ramchandra, Kadam, Shekhar, Ingale, Kailash, Patel, Hiren, Nyska, Abraham, Jain, Mukul R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843913/
https://www.ncbi.nlm.nih.gov/pubmed/36650455
http://dx.doi.org/10.1186/s12885-023-10530-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843913/
https://www.ncbi.nlm.nih.gov/pubmed/36650455
http://dx.doi.org/10.1186/s12885-023-10530-0

Ejemplares similares